TXG

NEUTRAL

$22.97 Live

10x Genomics, Inc. · NASDAQ

Target $23.38 (+1.8%)

$7.72 52W Range $26.45

TXG 10x Genomics, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

TXG Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Health Information Services

Current Price Live

$22.97

Analyst Target

$23.38

+1.8% Upside

52W High

$26.45

52W Low

$7.72

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 22, 2026

Market cap

$2.93B

P/E

N/A

ROE

-5.8%

Profit margin

-6.8%

Debt/Equity

0.11

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

TXG exhibits a stark divergence between its strong balance sheet liquidity and its poor operational health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a very low Debt/Equity ratio (0.11) and a robust Current Ratio (4.46), revenue growth has stagnated at 0.60% YoY. The stock is currently trading at a significant premium with a Forward P/E of 114.85, despite negative profit margins. Recent price recovery is strong, but insider selling and bearish technical trends suggest caution.

Key Strengths

Exceptional liquidity with a Current Ratio of 4.46

Very low leverage (Debt/Equity of 0.11)

Strong Gross Margins at 69.13%

Significant 1-year price recovery (+199.1%)

Consistent earnings beats in recent quarters

Key Risks

Stagnant revenue growth (0.60% YoY)

Poor financial trend indicated by Piotroski F-Score of 2/9

Extremely high valuation (Forward P/E 114.85)

Bearish insider sentiment with consistent selling by the CEO

Negative net profit and operating margins

AI Fair Value Estimate

Based on comprehensive analysis

$19.5

-15.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Recovery

Key drivers: Strong balance sheet, Stagnant top-line growth, Extreme valuation premium, Poor F-Score

Confidence

90%

Value

30/100

Ref P/E, PEG, Graham Number

Positives

P/B ratio of 3.68 is moderate for the sector

Watchpoints

Forward P/E of 114.85 is prohibitively high
No Graham Number available due to lack of earnings

Future

45/100

Ref Growth rates

Positives

Recent EPS growth is accelerating
Analyst target price ($23.38) is slightly above current price

Watchpoints

Revenue growth is nearly flat (0.60%)
Technical trend is heavily bearish (10/100)

Past

35/100

Ref Historical trends

Positives

Strong 1-year recovery from lows

Watchpoints

Devastating 5-year return of -88%

Health

25/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Low Debt/Equity
High Quick Ratio (3.95)

Watchpoints

Piotroski F-Score of 2/9 indicates weak financial health trends

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$22.97

Analyst Target

$23.38

Upside/Downside

+1.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TXG and closest competitors.

Updated 2026-04-21

Company	5Y	3Y	1Y	6M	1M	1W
TXG 10x Genomics, Inc. Primary	-88.0%	-57.2%	+199.1%	+76.3%	+20.0%	-7.4%
SUPN Supernus Pharmaceuticals, Inc. Peer	+66.0%	+41.6%	+67.1%	+2.4%	+4.3%	+1.4%
PRVA Privia Health Group, Inc. Peer	+4.4%	-7.2%	+1.4%	-5.9%	+11.3%	+7.4%
ARQT Arcutis Biotherapeutics, Inc. Peer	-30.1%	+98.3%	+53.6%	+31.6%	-14.4%	-5.2%
TARS Tarsus Pharmaceuticals, Inc. Peer	+124.0%	+341.3%	+36.0%	-7.3%	+2.3%	-9.2%

TXG

10x Genomics, Inc.

Primary

-88.0%

-57.2%

+199.1%

+76.3%

+20.0%

-7.4%

SUP

Supernus Pharmaceuticals, Inc.

Peer

+66.0%

+41.6%

+67.1%

+2.4%

+4.3%

+1.4%

PRV

Privia Health Group, Inc.

Peer

+4.4%

-7.2%

+1.4%

-5.9%

+11.3%

+7.4%

ARQ

Arcutis Biotherapeutics, Inc.

Peer

-30.1%

+98.3%

+53.6%

+31.6%

-14.4%

-5.2%

TAR

Tarsus Pharmaceuticals, Inc.

Peer

+124.0%

+341.3%

+36.0%

-7.3%

+2.3%

-9.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

114.85

N/A

3.68

4.56

3.88

-38.94

$2.93B

Profitability

Profit margins and return metrics

Profit Margin -6.77%

Operating Margin -9.42%

Gross Margin 69.13%

ROE -5.78%

ROA -6.4%

Growth

Revenue and earnings growth rates

Revenue Growth +0.6%

Earnings Growth N/A

Q/Q Revenue Growth +0.61%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.11

Low debt

Current Ratio

4.46

Strong

Quick Ratio

3.95

Excellent

Cash/Share

$4.1

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.2B

Gross Margin

68.1%

Op. Margin

-11.8%

Net Margin

-9.8%

Total Assets

$1.0B

Liabilities

$0.2B

Equity

$0.8B

Debt/Equity

0.31x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

96%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-02-12

$0.07

+276.2% surprise

2025-11-06

$-0.02

+67.4% surprise

2025-08-07

$0.28

+189.0% surprise

Healthcare Sector Comparison

Comparing TXG against 502 companies in the Healthcare sector (29 bullish, 154 neutral, 319 bearish)

Return on Equity (ROE)

-5.78%

This Stock

-94.61%

Sector Avg

-93.9% (Below Avg)

Profit Margin

-6.77%

This Stock

-15.81%

Sector Avg

-57.2% (Weaker)

Debt to Equity

0.11

This Stock

2.86

Sector Avg

-96.3% (Less Debt)

Revenue Growth

0.6%

This Stock

136.45%

Sector Avg

-99.6% (Slower)

Current Ratio

4.46

This Stock

4.65

Sector Avg

-4.1% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
TXG 10x Genomics, Inc.	NEUTRAL	$2.93B	-	-5.8%	-6.8%	$22.97
SUPN Supernus Pharmaceuticals, Inc.	NEUTRAL	$2.96B	-	-3.7%	-5.4%	$51.39	Compare
PRVA Privia Health Group, Inc.	NEUTRAL	$3.02B	126.42	4.0%	1.1%	$24.02	Compare
ARQT Arcutis Biotherapeutics, Inc.	BEARISH	$2.82B	-	-9.3%	-4.3%	$22.75	Compare
TARS Tarsus Pharmaceuticals, Inc.	NEUTRAL	$2.81B	-	-23.4%	-14.7%	$65.97	Compare

TXG 10x Genomics, Inc.

NEUTRAL

Mkt Cap

$2.9B

P/E

ROE

-5.8%

Price

$22.97

Compare with TXG

PRVA Privia Health...

Compare with TXG

Compare with TXG

Compare with TXG

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-14	SAXONOV SERGE WILSON	Chief Executive Officer	Sale	5,000	$122,784
2026-03-24	SAXONOV SERGE WILSON	Chief Executive Officer	Sale	15,000	$288,908
2026-03-03	SAXONOV SERGE WILSON	Chief Executive Officer	Gift	2,750	-
2026-03-02	SAXONOV SERGE WILSON	Chief Executive Officer	Sale	16,152	$367,097
2026-02-26	SAXONOV SERGE WILSON	Chief Executive Officer	Stock Award	157,895	-
2026-02-26	HINDSON BENJAMIN J	President	Stock Award	88,816	-
2026-02-26	TAICH ADAM	Chief Financial Officer	Stock Award	106,579	-
2026-02-25	TEICHMANN SARAH A.	Director	Sale	7,579	$147,108
2026-02-23	SAXONOV SERGE WILSON	Chief Executive Officer	Sale	9,632	$178,928
2026-02-23	HINDSON BENJAMIN J	President	Sale	7,826	$145,379
2026-02-23	TAICH ADAM	Chief Financial Officer	Sale	8,968	$166,593
2026-01-05	SAXONOV SERGE WILSON	Chief Executive Officer	Option Exercise	50,000	$60,000
2025-11-24	SAXONOV SERGE WILSON	Chief Executive Officer	Sale	13,261	$251,936
2025-11-24	HINDSON BENJAMIN J	President	Sale	8,283	$157,363
2025-11-24	TAICH ADAM	Chief Financial Officer	Sale	11,888	$225,852

SAXONOV SERGE WILSON

Chief Executive Officer

Sell

2026-04-14

5,000 shares · $122,784

SAXONOV SERGE WILSON

Chief Executive Officer

Sell

2026-03-24

15,000 shares · $288,908

SAXONOV SERGE WILSON

Chief Executive Officer

Gift

2026-03-03

2,750 shares

SAXONOV SERGE WILSON

Chief Executive Officer

Sell

2026-03-02

16,152 shares · $367,097

SAXONOV SERGE WILSON

Chief Executive Officer

Stock Award

2026-02-26

157,895 shares

HINDSON BENJAMIN J

President

Stock Award

2026-02-26

88,816 shares

TAICH ADAM

Chief Financial Officer

Stock Award

2026-02-26

106,579 shares

TEICHMANN SARAH A.

Director

Sell

2026-02-25

7,579 shares · $147,108

SAXONOV SERGE WILSON

Chief Executive Officer

Sell

2026-02-23

9,632 shares · $178,928

HINDSON BENJAMIN J

President

Sell

2026-02-23

7,826 shares · $145,379

TAICH ADAM

Chief Financial Officer

Sell

2026-02-23

8,968 shares · $166,593

SAXONOV SERGE WILSON

Chief Executive Officer

Option Exercise

2026-01-05

50,000 shares · $60,000

SAXONOV SERGE WILSON

Chief Executive Officer

Sell

2025-11-24

13,261 shares · $251,936

HINDSON BENJAMIN J

President

Sell

2025-11-24

8,283 shares · $157,363

TAICH ADAM

Chief Financial Officer

Sell

2025-11-24

11,888 shares · $225,852

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K

2026-02-13

TXG filed its annual 10-K on February 13, 2026, which includes detailed sections on business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K

2026-02-12

TXG filed an 8-K on February 12, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-01-12

8-K

2025-11-14

10-Q

2025-11-07

TXG's 10-Q filing dated November 7, 2025, indicates the company has engaged in unregistered sales of equity securities. While specific financial metrics were not provided in the excerpts, the filing includes dedicated sections for risk factors and the use of proceeds from equity sales.

8-K

2025-11-06

TXG filed an 8-K on November 6, 2025, likely to announce its third-quarter financial results.

10-Q

2025-08-08

TXG filed its 10-Q on August 8, 2025. The provided excerpt identifies 26 risk factors, although specific financial highlights were not included in the available text.

8-K

2025-08-07

TXG filed an 8-K on August 7, 2025, likely to announce its second-quarter financial results.

8-K

2025-06-05

8-K

2025-05-14

TXG filed an 8-K on May 14, 2025, likely to announce its first-quarter financial results.

10-Q

2025-05-09

8-K

2025-05-08

DEF 14A

2025-04-14

10-K

2025-02-13

8-K

2025-02-12

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

13 analysts

Canaccord Genuity

2026-04-20

Maintains

Buy Buy

B of A Securities

2026-04-20

Maintains

Neutral Neutral

Barclays

2026-04-14

Maintains

Overweight Overweight

Citigroup

2026-04-07

Maintains

Neutral Neutral

William Blair

2026-03-31

Market Perform Outperform

Stifel

2026-03-02

Maintains

Buy Buy

UBS

2026-02-20

Maintains

Neutral Neutral

Stifel

2026-02-13

Maintains

Buy Buy

TD Cowen

2026-02-13

Maintains

Hold Hold

Leerink Partners

2026-01-27

Maintains

Market Perform Market Perform

Past News Coverage

Recent headlines mentioning TXG from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

TXG

TXG 10x Genomics, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!